Pharmacokinetic Study Of A Bioabsorbable Rapamycin Eluting Stent Manufactured In China In Miniswine Coronary Model

BackgroudThe long-term clinical efficacy of intracoronary stenting is limited by restenosis, which occurs in 20% to 30% of patients. The efficiency of the nonbiodegradable drug-eluting stent (DES) (such as Cypher stent from Cordis Inc. and Taxus stent from Boston Scientific Inc.) for preventing in-stent-restenosis (ISR) have been proved by many animal and clinical studies. However, recently, more attentions have been paid to problems of the nonbioabsorbable DES such as delaying of endothelialization, late in stent thrombosis, malapposition, stent related aneurysm, polymer caused inflammatory reaction and allergic response, etc. As pointed out by some studies, up to now, the nonbioabsorbable DES in use can not decrease the mortality rate and the incidence of acute myocardial infarction. These results indicate the nonbioabsorbable DES needs more improvements. Therefore, the bioabsorbable DES which has a complete degradation profile may be a new important direction of DES. So far most of DES are imported from US or European countries. It is necessary to approach a way to manufacture the Drug-eluting stent in...